SSG
NRIX icon

Summit Securities Group’s Nurix Therapeutics NRIX Stock Holding History

Summit Securities Group’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.1K Buy
+779
New +$12.9K ﹤0.01% 630
2025
Q2 		– Sell
-155
Closed -$1.84K – 1313
2025
Q1 		$1.84K Buy
+155
New +$2.59K ﹤0.01% 674

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Summit Securities Group's NRIX Position: Q1 2026 in Review

Summit Securities Group opened a new position in Nurix Therapeutics (NRIX) in Q1 2026: 779 shares worth $12.1K. The stake represents ﹤0.01% of the portfolio and ranks #630 among its holdings. This is a return to the name: Summit Securities Group previously reported a position in NRIX as recently as Q1 2025.

Summit Securities Group first reported a position in NRIX in Q1 2025 and has held it in 2 quarters since. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Summit Securities Group held 779 shares of Nurix Therapeutics worth $12.1K as of Q1 2026.
  • Nurix Therapeutics was a new Summit Securities Group position in Q1 2026.
  • Nurix Therapeutics made up ﹤0.01% of Summit Securities Group's portfolio in Q1 2026, its #630 holding.
  • Summit Securities Group first reported a position in Nurix Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Summit Securities Group's 13F filing for Q1 2026, filed 30 Apr 2026.